| scholarly article | Q13442814 |
| P50 | author | Je-Hwan Lee | Q41274798 |
| P2093 | author name string | Hyeoung-Joon Kim | |
| Jun Ho Jang | |||
| Yoo-Jin Kim | |||
| Jae-Yong Kwak | |||
| P2860 | cites work | Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. | Q50534602 |
| Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. | Q53345234 | ||
| Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes. | Q53381432 | ||
| Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. | Q53429887 | ||
| Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. | Q53481174 | ||
| Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation | Q59315414 | ||
| Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders | Q73774661 | ||
| Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation | Q74371947 | ||
| Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases | Q74752110 | ||
| Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes | Q80768443 | ||
| Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes | Q82292929 | ||
| Azacitidine: a new medication associated with Sweet syndrome | Q83877087 | ||
| Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome | Q86157192 | ||
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 | ||
| International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 | ||
| Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System | Q33380307 | ||
| Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy | Q33390778 | ||
| DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes | Q33628772 | ||
| Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia | Q33861150 | ||
| Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 | ||
| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 | ||
| DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome | Q34539944 | ||
| Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. | Q34559054 | ||
| Revised international prognostic scoring system for myelodysplastic syndromes | Q34639717 | ||
| Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome | Q34924442 | ||
| 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation | Q34960346 | ||
| Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) | Q35265820 | ||
| Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. | Q35835657 | ||
| Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine | Q36029093 | ||
| Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. | Q36036263 | ||
| Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes | Q36222935 | ||
| Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure | Q36877036 | ||
| Cause of death in patients with lower-risk myelodysplastic syndrome | Q37120849 | ||
| Prognostic classification and risk assessment in myelodysplastic syndromes | Q37722941 | ||
| Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes | Q37723835 | ||
| Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. | Q37723842 | ||
| Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group | Q37766785 | ||
| Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion | Q37770644 | ||
| Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management | Q38018571 | ||
| Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. | Q38455680 | ||
| Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment | Q38487533 | ||
| Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes | Q39527812 | ||
| Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome | Q40352317 | ||
| Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome | Q40604775 | ||
| Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy | Q42124715 | ||
| Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. | Q43115411 | ||
| Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program | Q43164242 | ||
| Survival benefits with transplantation in secondary AML evolving from myelodysplastic syndrome with hypomethylating treatment failure | Q43467909 | ||
| Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. | Q43988719 | ||
| A prognostic score for patients with lower risk myelodysplastic syndrome | Q44103626 | ||
| Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries | Q44233301 | ||
| Azacitidine-associated Sweet's syndrome | Q44975267 | ||
| Myelodysplastic syndromes--coping with ineffective hematopoiesis | Q45259429 | ||
| Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution | Q45353520 | ||
| Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. | Q45959783 | ||
| 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. | Q45960014 | ||
| Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients | Q46052631 | ||
| Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes | Q46102907 | ||
| Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD. | Q46318962 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 87-98 | |
| P577 | publication date | 2013-06-25 | |
| P1433 | published in | Blood research | Q26842305 |
| P1476 | title | Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations | |
| P478 | volume | 48 |
| Q38608434 | Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy |
| Q38998074 | Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes |
| Q38440284 | Gingival enlargement in myelodysplastic syndrome |
Search more.